In Stamford, Connecticut on April 14, 2025, Cara Therapeutics, Inc. disclosed a major decision. The company, listed as CARA on Nasdaq, revealed that its Board of Directors has greenlit a 1-for-3 reverse stock split for its current common stock shares.